Rizaport® is a novel, competitive and differentiated oral thin film
formulation of rizatriptan for the acute treatment of migraine.
Key
Licensing Highlights
- Orally disintegrating film, without need for
water, provides exceptional convenience for migraine patients who experience nausea or have
trouble swallowing
- Rizaport® is the first oral thin film using IntelGenx
proprietary drug delivery technology, VersaFilmTM,
for the
acute treatment of migraine with or without aura
- Containing rizatriptan, one of the most effective triptans
- Bioequivalent to Maxalt-MLT® (Merck & Co.)
- The first rizatriptan oral disintegrating film to achieve
approval in the E.U. and pending U.S. FDA approval
- USPTO has granted a patent protecting Rizaport® for 15+ years
- Manufactured at IntelGenx through a bona fide process
offering better cost-effectiveness compared to Maxalt-MLT®
- IntelGenx offers strong expertise in formulation and process development as well as manufacturing capability
- Strong management team with a proven track record of success in working with commercialization partners
Our commercialization partners are Exeltis, a subsidiarity of the Chemo Group (Spain) and Pharmatronic (Republic of Korea).
We are currently looking for a partnership or alliance opportunity to commercialize Rizaport® in any territories worldwide apart from Spain and the Republic of Korea.
CA
